Tag:

Johnson & Johnson

Latest Headlines

Latest Headlines

J&J's 2018 Remicade patent smacked down at PTO again

Johnson & Johnson said the U.S. Patent and Trademark Office rejected a 2018 Remicade patent for the second time, putting the blockbuster anti-inflammatory's exclusivity in jeopardy. But the company also said it would appeal, a process that could take years.

Boston Sci partners with Brainlab, as revenue outlook goes flat and legal costs weigh

Boston Scientific is looking determinedly toward the future with a new partnership with deep brain stimulation player Brainlab and positive data for its peripheral artery disease drug-eluting stent. But the past keeps weighing upon it as litigation costs pile up from vaginal mesh lawsuits and the recent settlement with Johnson & Johnson over the long-standing Guidant dispute.

Belgian molecular Dx player Biocartis raises €100M to advance recent launch of Idylla system

Biocartis has raised €100 million ($109 million) in an IPO that's also managed to trade up in recent days. The company could bring in up to €115 million ($126 million) if the bankers exercise their overallotment. That should be the case, since the IPO was highly oversubscribed--the company said it had more than €650 million ($710 million) in investor demand for the IPO.

From the pharma C-suite: Notable, quotable remarks on Asia, emerging markets for Q1

FiercePharmaAsia combs earnings calls by major drug companies for notable and quotable nuggets on emerging markets and Asia to track the latest sales trends and insight into business outlooks in markets as diverse as China, India and Japan to Southeast Asia.

Western firms form band of brothers, but welcome others, in Asian medical device association

Major Western device and medical technology firms launched Asia Pacific Medical Technology Association, or APACMed, pledging the association would unite a fragmented effort to work with regulators across a region that is both lucrative and frustrating on issues ranging from import rules to public tender guidelines.

J&J pulls contraceptives in Canada on potency worries

J&J's Janssen unit is recalling one lot of Ortho-Cept contraceptive tablets because of the potential that the potency of the two active ingredients may not meet specifications, Health Canada reports.

J&J recalls contraceptives for subpotency

J&J's Janssen unit is recalling one lot of Ortho-Cept tablets because of the potential that the potency of the two active ingredients may not meet specifications, Health Canada reports.

J&J backs Scottish biotech incubator at ex-Merck site

Johnson & Johnson has extended its tendrils into another biotech incubator. Having played a role in the formation of incubators in the U.S., Canada and Israel in recent years, the Big Pharma has now lent its support to an initiative to foster the development of Scottish life science startups.

J&J banking on improved insulin delivery tech to cure diabetes business woes

Johnson & Johnson's diabetes care business experienced a year-over-year revenue decline of 2.2% in 2015 and fell 8.7% for the year. But J&J executives are optimistic about a turnaround, citing the recent launch of the drug-delivering Animas Vibe continuous glucose monitor and insulin pump, and longer term plans for a wearable insulin pump.

Study: Schizophrenics on J&J's injectable fare better than those on oral meds

In a study, Janssen Pharmaceuticals' once-a-month injectable for schizophrenia resulted in better outcomes than daily oral competitors, as measured by real-world (as opposed to strictly clinical) outcomes like arrest or psychiatric hospitalization.